Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Targets high-growth eye care expansion push
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
PMDA is regarded among the most stringent regulatory bodies globally
Subscribe To Our Newsletter & Stay Updated
